At a glance
- Originator Fujisawa
- Class Antiplatelets; Small molecules
- Mechanism of Action Fibrinogen inhibitors; GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 10 May 1999 New profile
- 10 May 1999 Preclinical development for Thrombosis in Japan (PO)